Which hospitals provide the application and treatment of ivonib

Ivosidenib (Ivosidenib) is a small molecule inhibitor of mutated IDH1 (isocitrate dehydrogenase 1). It is mainly used to treat certain types of blood cancers, especially acute myeloid leukemia (AML). Myelodysplastic syndrome(MDS)etc. IDH1 gene mutations are common in certain tumors. Such mutations can lead to abnormalities in metabolic pathways, thereby promoting the proliferation and survival of tumor cells.

With the rapid development of precision medicine, more and more hospitals and oncology centers in China have begun to apply ivonib, especially in the fields of hematology and medical oncology. For example, some tertiary hospitals have launched molecular targeted therapy projects for patients with IDH1 mutations. Some hospitals have specialized multidisciplinary consultation (MDT) teams for AML and cholangiocarcinoma, which can develop personalized treatment plans for patients.

The specific application process usually includes genetic testing to confirm that IDH1 mutation is positive. After the IDH1 mutation is positive, the attending doctor will evaluate the patient's overall condition and formulate an ivonib treatment plan based on guideline recommendations. Since ivonib is an imported original drug, its availability in China is currently relatively limited. Some hospitals introduce it through special drug channels or overseas direct procurement. Patients need to consult the hospital pharmacy or international medical department in advance to understand the specific drug supply situation.

At the same time, some institutions that are well-known for their international medical services can also provide patients with prescription services for ivonib and assist in obtaining drugs. In addition, large cancer treatment centers are also actively promoting the clinical application of ivonib. It should be reminded that regular follow-up is required during the use of ivonib, and ECG changes and blood routine indicators must be closely monitored to ensure the safety and maximum efficacy of the medication.

Overall, as precision medicine continues to gain popularity in China, ivonib will be more widely used in the future, and patients will be able to get treatment opportunities with this innovative therapy in more cities.

Reference: https://www.tibsovo.com/